Villaris to receive $70M up front, ~$310M upon achievement of development & regulatory milestones along with ~$1.05B in commercial milestones on net sales of the product. Incyte gets an exclusive global right to develop & commercialize auremolimab for all uses, incl. vitiligo & other autoimmune and inflammatory diseases
The acquisition will complement Incyte’s existing inflammation & autoimmunity portfolio to advance the treatment options for vitiligo patients with potential applications for auremolimab beyond dermatology
Auremolimab (VM6) is an anti-IL-15Rβ mAb & is expected to enter clinical development in 2023. In preclinical studies, auremolimab showed a high potency, selectivity & efficacy in vitiligo
Ref: Businesswire | Image: Incyte
